
|Articles|April 12, 2018
Ipsos Healthcare Releases Pan-Cancer Testing Monitor in Australia
Advertisement
Ipsos Healthcare-the global healthcare business of Ipsos-announced the expansion of its syndicated Pan-Cancer Testing Monitor (PCTM) to the Australian market.
The study gathers insights from medical oncologists and pathologists on topics such as awareness and current utilization of pan-cancer tests, perceived advantages and disadvantages, and drivers and barriers to use. In addition, it incorporates de-identified patient record forms for patients who were recently tested with a pan-cancer test.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
2
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
3
Alnylam Enters $2 Billion Strategic AI Collaboration with Inceptive
4
New FDA Draft Guidance Targets Gene Therapy Submission Burden by Allowing Use of Existing CMC and Scientific Knowledge
5




